Risk & Volatility
Interpace Biosciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Titan Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
Profitability
This table compares Interpace Biosciences and Titan Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Interpace Biosciences | 65.25% | 219.07% | 105.05% |
| Titan Medical | N/A | -82.31% | -51.47% |
Valuation and Earnings
This table compares Interpace Biosciences and Titan Medical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Interpace Biosciences | $38.73 million | 0.21 | $24.58 million | ($0.05) | -36.00 |
| Titan Medical | $17.63 million | 1.34 | $6.95 million | $0.05 | 4.16 |
Interpace Biosciences has higher revenue and earnings than Titan Medical. Interpace Biosciences is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
5.7% of Interpace Biosciences shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 5.5% of Interpace Biosciences shares are held by insiders. Comparatively, 0.0% of Titan Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Interpace Biosciences beats Titan Medical on 7 of the 11 factors compared between the two stocks.
About Interpace Biosciences
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
About Titan Medical
Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada.
Receive News & Ratings for Interpace Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
